[wannabe]

Multiple sclerosis

Study will pair two medications

If two heads are better than one in solving problems, could two drugs be better than one in treating multiple sclerosis?

That's what researchers at St. Louis University will try to find out in a new study that will offer a pair of approved drugs to some patients.

Study participants will be randomly divided into three groups: A fourth will received Interferon beta-1a (Avonex), a fourth will be given Copaxone and half will take both.

The study will last three years and will involve 1,000 patients at 70 centers nationwide. To be eligible, you must be between 18 and 60 and have relapsing-remitting MS. You must also have had at least two attacks of symptoms in the last three years and cannot have ever taken either study medication in the past.

For complete details, call (314) 577-8026.

http://www.belleville.com/mld/bellev...g/16166772.htm

[SallyC]

As you can see, these Combo and comparison studies were announced a couple of years ago, Wannabe. Maybe the big Tysabi rush put a stop to them and they are starting up again.

This particular artical was, as you can see, updated in November of 2004???

Thanks for posting.

Neurology Clinical Trials
http://www.hsc.stonybrook.edu/som/neurology/clinictrials.cfm

These are the clinical trials ongoing in the Department of Neurology. You will be able to find the name of trial, purpose of study, contact person for potential volunteers, phone number of contact person and email address of contact person.
-------------------------------------------

Multiple Sclerosis

(Updated November 15, 2004)

Name of TrialCombiRx

Study DrugsAvonex (Interferon beta-1a) and Copaxone (Glatiramer Acetate).

Purpose of StudyA three arm study to compare the efficacy of Avonex alone, Copaxone alone, or both Avonex and Copaxone as measure by the number of relapses after initiation of the study drug (s).

PatientMust have a diagnosis of Relapsing Remitting Multiple Sclerosis with no prior history of being treated with any interferon (Rebif, Betaseron, Avonex) or with Copaxone.

Contact(631) 444-3448
--------------------------------------------

Name of TrialSerono RVC

Study DrugsRebif (Interferon beta-1a) and Copaxone (Glatiramer Acetate)

Purpose of StudyTo compare the efficacy of Rebif versus Copaxone for the treatment of Relapsing Remitting Multiple Sclerosis as measured the number of relapse (s) after initiation of the study drug.

PatientMust have a diagnosis of Relapsing Remitting Multiple Sclerosis with no prior history of being treated with any interferon (Rebif, Betaseron, Avonex) or with Copaxone

Contact(631) 444-3448
----------------------------------------------

Name of TrialBeyond

Study DrugsBetaseron (Interferon beta-1b) and Copaxone (Glatiramer Acetate)

Purpose of StudyTo compare the efficacy of two different Betaseron doses versus Copaxone for the treatment of Relapsing Remitting Multiple Sclerosis as measured the number of relapse (s) after initiation of the study drug.

PatientMust have a diagnosis of Relapsing Remitting Multiple Sclerosis with no prior history of being treated with any interferon (Rebif, Betaseron, Avonex) or with Copaxone.

Contact(631) 444-3448
__________________________________________________

Name of Trial Achieve

Study DrugsBetaseron (Interferon beta-1b) or Rebif (Interferon beta-1a) and Copaxone (Glatiramer Acetate)

Purpose of StudyTo measure the efficacy of Interferon versus Copaxone in the treatment of Relapsing Remitting Multiple Sclerosis as measured the number of relapse (s) after initiation of the study drug.

PatientMust have a diagnosis of Relapsing Remitting Multiple Sclerosis and currently be taking either Betaseron or Rebif for a minimum of the past 1 year.

Contact(631) 444-3448
---------------------------------------------

Name of TrialAbove

Study DrugsAvonex (Interferon beta-1a) and Betaseron (Interferon beta-1b)

Purpose of StudyTo measure the efficacy of two different Interferons, Avonex and Betaseron

PatientMust have a diagnosis of Relapsing Remitting Multiple Sclerosis and currently be taking Avonex for a minimum of the past 1 year.

Contact(631) 444-3448
---------------------------------------------
Name of TrialNeurocrine

Study DrugsNBI-5788 (an experimental agent) and Placebo

Purpose of StudyTo test the efficacy, safety and tolerability (Phase II Clinical Trial) of NBI-5788 versus Placebo in patients with Relapsing Remitting Multiple Sclerosis.

PatientMust have Relapsing Remitting Multiple Sclerosis

Contact(631) 444-3448
--------------------------------------------
Name of TrialPreCISe

Study DrugsCopaxone (Glatiramer Acetate) and Placebo

Purpose of StudyTo test the efficacy of Copaxone in patients who have had a single clinical episode suggestive of Multiple Sclerosis as measured by the time to an additional attack after initiation of the study drug versus placebo.

PatientA history of one, unifocal, well defined clinical event that is highly suggestive of Multiple Sclerosis without yet meeting formal criteria.

Contact(631) 444-3448
---------------------------------------------
Name of TrialGender Based Questionnaire

Study Drugsnone

Purpose of StudyTo explore issues related to Multiple Sclerosis and Gender, including but not limited to pregnancy and breast feeding in patients with Multiple Sclerosis.

PatientFemale with a diagnosis of Multliple Sclerosis who is willing to fill out multiple questionnaires (mailed to patient)

Contact(631) 444-3448